Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
AssigneeThe Regents of the University of California
InventorsJonathan Braun, Stephan R. Targan
Life of this patent
Estimating the term…
Abstract
The present invention provides novel methods of screening for ulcerative colitis and Crohn's disease which include the detection of two disparate autoantibodies: pANCA and VH3-15 autoantibody. The present invention also provides kits for screening ulcerative colitis and Crohn's disease.
Claims66
A method of screening a patient for Crohn's disease ("CD") and ulcerative colitis ("UC"), comprising:
- (a) determining the amount of VH3-15 autoantibody in a sample from the patient,
- (b) detecting the presence or absence of pANCA in a sample from the same patient,
- wherein an amount of VH3-15 autoantibody in the sample which exceeds the amount of VH3-15 autoantibody in a VH3-15 assay control and the absence of pANCA indicates CD, and
- wherein an amount of VH3-15 autoantibody in the sample that does not exceed the amount of VH3-15 autoantibody in a VH3-15 assay control and the presence of pANCA indicates UC.
A method of screening a patient for Crohn's disease ("CD") and ulcerative colitis ("UC"), comprising:
- (a) contacting a first sample with anti-VH3-15 idiotypic antibody material under conditions suitable to form a VH3-15 autoantibody-containing immune complex;
- (b) determining the amount of VH3-15 autoantibody in the first sample by detecting the amount of VH3-15 autoantibody-containing complex formed in step (a);
- (c) contacting a second sample from the patient with neutrophil and a specific binding agent for pANCA under conditions suitable to form a pANCA-containing immune complex;
- (d) detecting the presence or absence of pANCA-containing immune complex formed in step (c), wherein the absence of pANCA-containing immune complex indicates the absence of pANCA;
- (e) contacting a third sample with DNase-treated neutrophil and a specific binding agent for pANCA under conditions suitable to form a pANCA-containing immune complex;
- and
- (f) detecting the presence or absence of pANCA-containing immune complex formed in step (e), wherein the presence of an immune complex in step (d) and the absence of an immune complex in step (e) indicates the presence of pANCA, and
- wherein an amount of VH3-15 autoantibody in the sample which exceeds the amount of VH3-15 autoantibody in a VH3-15 assay control and the absence of pANCA indicates CD, and
- wherein an amount of VH3-15 autoantibody in the sample that does not exceed the amount of VH3-15 autoantibody in a VH3-15 assay control and the presence of pANCA indicates UC.
A kit for screening a patient for ulcerative colitis and Crohn's disease, comprising anti-VH3-15 idiotypic antibody material and a reagent selected from the group consisting of neutrophil and DNase treated neutrophil.
Dependencies are inferred from the claim text.